Novavax: ‘Substantial Doubt’ Around Ability to Continue

Covid-19 vaccine manufacturer


Novavax


said Tuesday that there is “substantial doubt” about its ability to continue operating through this year.

In a quarterly earnings report issued after the market closed, the company said that it expects to have enough cash to fund its operations through the year, but that expectation is “subject to significant uncertainty” related to 2023 revenues, among other factors.